Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Whole Body CD8 + T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

Jaap A. van Doesum, Kylie Keijzer, Janneke W. de Boer, Nienke A.M. Smit, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Frank R. Pierik, Gerwin A. Huls, Lisanne V. van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P. Williams, Alexander Ungewickell, Sjoerd G. Elias, Elisabeth G.E. de Vries, Anne G.H. Niezink, Tom van Meerten

Blood (2024) 144 (Supplement 1): 1037.

https://doi.org/10.1182/blood-2024-199474

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Gloria Iacoboni, Pere Barba, Irma Khvedelidze, Maud Ngoya, Paolo Corradini, Pierre Sesques, Marion Subklewe, Maria Gomes Da Silva, Gilles Crochet, Jarosław Dybko, Izaskun Zeberio, Alejandro Martín García-Sancho, Tom van Meerten, Maeve O'Reilly, Bertram Glass, Ana Maria Sureda Balari, Peter Dreger, Olivier Hermine, Ali Bazarbachi

Blood (2024) 144 (Supplement 1): 3656.

https://doi.org/10.1182/blood-2024-205389

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients

Blood (2024) 144 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2024-209879

Published: 2024

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

Kylie Keijzer, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Gerwin A. Huls, Lisanne V. van Dijk, Tom van Meerten, Anne G.H. Niezink

Blood (2023) 142 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2023-173947

Published: 2023

Journal Articles

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Hilde T Van Der Galien, Hilde AM Kooistra, Robby Kibbelaar, Nic JGM Veeger, Marcel Nijland, Geert A. Huls, Tom Van Meerten, Rozemarijn S Van Rijn

Blood (2023) 142 (Supplement 1): 444.

https://doi.org/10.1182/blood-2023-185993

Published: 2023

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Blood (2022) 140 (Supplement 1): 1957–1959.

https://doi.org/10.1182/blood-2022-169164

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Blood (2022) 140 (Supplement 1): 10399–10401.

https://doi.org/10.1182/blood-2022-156117

Published: 2022

Journal Articles

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 8347–8349.

https://doi.org/10.1182/blood-2022-168991

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy

Anne Niezink, Jaap van Doesum, Max Beijert, Marcel Nijland, Hans Langendijk, Dianne Busz, Anne P.G. Crijns, Gerwin A. Huls, Tom Van Meerten

Blood (2021) 138 (Supplement 1): 2510.

https://doi.org/10.1182/blood-2021-151404

Published: 2021

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Blood (2021) 138 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2021-147403

Published: 2021

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

https://doi.org/10.1182/blood-2021-148039

Published: 2021

Journal Articles

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Sabine Haggenburg, Birgit I. Lissenberg-Witte, Robert S. Van Binnendijk, Gerco Den Hartog, Bhoekhan S. Michel, Nienke J.E. Haverkate, Dennis M. De Rooij, Annoek E.C. Broers, Pim G.N.J. Mutsaers, Tom Van Meerten, Jaap van Doesum, Arnon P. Kater, Sonja Zweegman, Marit J. Van Gils, Bram Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof

Blood (2021) 138 (Supplement 1): 754.

https://doi.org/10.1182/blood-2021-150379

Published: 2021

Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD

Blood (2019) 134 (Supplement_1): 701.

https://doi.org/10.1182/blood-2019-123442

Published: 2019

Journal Articles

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Max Topp, MD, Tom Van Meerten, MD PhD, Roch Houot, MD PhD, Monique C. Minnema, Noel Milpied, MD, Pieternella J. Lugtenburg, MD PhD, Catherine Thieblemont, MD PhD, Martin Wermke, MD, Kevin Song, MD, Irit Avivi, MD, John Kuruvilla, MD, Ulrich Dührsen, Prof, MD PhD, Rachel Chu, PhD, Lianqing Zheng, PhD, Vicki Plaks, PhD, Anne Kerber, MD, Marie Jose' Kersten, MD PhD

Blood (2019) 134 (Supplement_1): 243.

https://doi.org/10.1182/blood-2019-126081

Published: 2019

Journal Articles

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Tom Van Meerten, Renee Bouwstra, Bsc, Yuan He, PhD, de Boer Janneke, Bsc, Hilde Kooistra, MD PhD, Rudolf Fehrmann, MD PhD, Emanuele Ammatuna, MD PhD, Gerwin Huls, MD PhD, Edwin Bremer, PhD

Blood (2018) 132 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2018-99-114561

Published: 2018

NARROW

Whole Body CD8 + T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only